Susquehanna International Group
ITCI

Susquehanna International Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Susquehanna International Group’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-125,800
Closed -$16.6M – 14053
2025
Q1 		$16.6M Buy
125,800
+84,600
+205% +$10.5M ﹤0.01% 1923
2024
Q4 		$3.44M Sell
41,200
-48,300
-54% -$3.97M ﹤0.01% 4205
2024
Q3 		$6.55M Buy
89,500
+11,700
+15% +$879K ﹤0.01% 3174
2024
Q2 		$5.33M Sell
77,800
-47,200
-38% -$3.27M ﹤0.01% 3340
2024
Q1 		$8.65M Buy
125,000
+4,300
+4% +$296K ﹤0.01% 2823
2023
Q4 		$8.64M Buy
120,700
+67,300
+126% +$3.87M ﹤0.01% 2829
2023
Q3 		$2.78M Sell
53,400
-49,000
-48% -$2.85M ﹤0.01% 4518
2023
Q2 		$6.48M Sell
102,400
-27,600
-21% -$1.72M ﹤0.01% 3115
2023
Q1 		$7.04M Sell
130,000
-13,800
-10% -$667K ﹤0.01% 2953
2022
Q4 		$7.61M Buy
143,800
+11,000
+8% +$551K ﹤0.01% 2643
2022
Q3 		$6.18M Buy
132,800
+2,400
+2% +$125K ﹤0.01% 2844
2022
Q2 		$7.44M Sell
130,400
-40,800
-24% -$2.31M ﹤0.01% 2604
2022
Q1 		$10.5M Sell
171,200
-88,800
-34% -$4.61M ﹤0.01% 2492
2021
Q4 		$13.6M Buy
260,000
+40,200
+18% +$1.69M ﹤0.01% 2295
2021
Q3 		$8.19M Buy
219,800
+79,400
+57% +$2.76M ﹤0.01% 3165
2021
Q2 		$5.73M Sell
140,400
-66,900
-32% -$2.47M ﹤0.01% 3795
2021
Q1 		$7.03M Sell
207,300
-90,800
-30% -$3.15M ﹤0.01% 3343
2020
Q4 		$9.48M Sell
298,100
-343,600
-54% -$9.03M ﹤0.01% 2566
2020
Q3 		$16.5M Buy
641,700
+279,500
+77% +$6.38M ﹤0.01% 1674
2020
Q2 		$9.3M Buy
362,200
+66,100
+22% +$1.34M ﹤0.01% 2219
2020
Q1 		$4.55M Sell
296,100
-867,700
-75% -$18.8M ﹤0.01% 2703
2019
Q4 		$39.9M Buy
1,163,800
+910,700
+360% +$10.9M 0.01% 952
2019
Q3 		$1.89M Sell
253,100
-700,800
-73% -$6.72M ﹤0.01% 4307
2019
Q2 		$12.4M Buy
953,900
+408,200
+75% +$5.24M ﹤0.01% 1687
2019
Q1 		$6.65M Sell
545,700
-212,400
-28% -$2.71M ﹤0.01% 2138
2018
Q4 		$8.63M Buy
758,100
+337,700
+80% +$5.45M ﹤0.01% 1746
2018
Q3 		$9.12M Buy
420,400
+96,900
+30% +$2.03M ﹤0.01% 2031
2018
Q2 		$5.72M Buy
323,500
+192,500
+147% +$3.91M ﹤0.01% 2548
2018
Q1 		$2.76M Buy
131,000
+103,900
+383% +$2.02M ﹤0.01% 3392
2017
Q4 		$392K Sell
27,100
-16,500
-38% -$255K ﹤0.01% 7100
2017
Q3 		$688K Buy
+43,600
New +$640K ﹤0.01% 5964
2017
Q2 		– Sell
-91,100
Closed -$1.48M – 9960
2017
Q1 		$1.48M Sell
91,100
-48,400
-35% -$700K ﹤0.01% 4308
2016
Q4 		$2.1M Buy
139,500
+3,500
+3% +$49.4K ﹤0.01% 3957
2016
Q3 		$2.07M Sell
136,000
-65,500
-33% -$2.65M ﹤0.01% 3513
2016
Q2 		$7.82M Buy
201,500
+162,000
+410% +$5.82M ﹤0.01% 1680
2016
Q1 		$1.1M Sell
39,500
-14,900
-27% -$497K ﹤0.01% 4898
2015
Q4 		$2.93M Sell
54,400
-23,500
-30% -$1.19M ﹤0.01% 3328
2015
Q3 		$3.12M Buy
+77,900
New +$2.54M ﹤0.01% 3434

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.16B AUM 18.64% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Susquehanna International Group's ITCI Position: Q1 2025 in Review

Susquehanna International Group sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 9,286 shares — an estimated $1.16M sold.

Susquehanna International Group first reported a position in ITCI in Q2 2014 and held it in 34 quarters. The position peaked at $17.4M in Q3 2017. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Susquehanna International Group reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Susquehanna International Group sold 9,286 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $1.16M.
  • Susquehanna International Group first reported a position in Intra-Cellular Therapies Inc. in Q2 2014 and held it in 34 quarters.
  • Susquehanna International Group's Intra-Cellular Therapies Inc. position peaked at $17.4M in Q3 2017.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.